Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 1,229 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $16.00, for a total value of $19,664.00. Following the completion of the transaction, the insider now owns 1,234,363 shares in […]
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) had its price target raised by HC Wainwright from $45.00 to $50.00 in a research report report published on Monday, The Fly reports. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q4 2023 earnings at ($0.72) EPS, FY2023 earnings at ($2.65) EPS, FY2024 earnings at ($2.45) EPS, […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) shares fell 5.1% during trading on Thursday . The stock traded as low as $13.60 and last traded at $13.67. 157,126 shares changed hands during trading, a decline of 82% from the average session volume of 886,443 shares. The stock had previously closed at $14.41. Analyst Ratings […]
Martingale Asset Management L P purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 32,042 shares of the company’s stock, valued at approximately […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) shares gapped down prior to trading on Wednesday . The stock had previously closed at $14.37, but opened at $14.00. Day One Biopharmaceuticals shares last traded at $14.78, with a volume of 923,241 shares trading hands. Wall Street Analyst Weigh In Several analysts have recently commented on […]